Abstract
Abstract Professor Hall will have reviewed his studies on the impact of lower doses of tamoxifen on changes in breast density, an important risk factor. Here I will review the work of Professor Decensi’s team on the ability of 5mg/d of tamoxifen (baby-Tam) on the progression rate of DCIS (69%) and other intraepithelial lesions (11% LCIS, 20% atypical ductal hyperplasia). This trial involved 500 pre- and postmenopausal women randomized equally between baby-Tam and placebo with a 9.7 year median follow up. All breast cancer progression (invasive (77%) and DCIS (23%)) was reduced by 42% (25 vs 41 events, P = 0.03) and contralateral tumours by 64% (6 vs 16 events, P = 0.025). No significant increase was seen in any side effect (Table). I will also briefly discuss their new award for a project to compare baby Tam to baby exemestane in a randomized trial in a similar population as above, initially for side effects, but also subsequently for efficacy. Professor Hall will have reviewed his studies on the impact of lower doses of tamoxifen on changes in breast density, an important risk factor. Here I will review the work of Professor Decensi’s team on the ability of 5mg/d of tamoxifen (baby-Tam) on the progression rate of DCIS (69%) and other intraepithelial lesions (11% LCIS, 20% atypical ductal hyperplasia). This trial involved 500 pre- and postmenopausal women randomized equally between baby-Tam and placebo with a 9.7 year median follow up. All breast cancer progression (invasive (77%) and DCIS (23%)) was reduced by 42% (25 vs 41 events, P = 0.03) and contralateral tumours by 64% (6 vs 16 events, P = 0.025). No significant increase was seen in any side effect (Table). I will also briefly discuss their new award for a project to compare baby Tam to baby exemestane in a randomized trial in a similar population as above, initially for side effects, but also subsequently for efficacy. Citation Format: J. Cuzick, P. Hall. Baby-TAM Impact on disease progression [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr TC-01.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.